## Joe Shaw Bio

## His brief bio is:

Mr. Shaw has over 20 years experience in the development and commercialization of biotechnology innovations. He has extensive experience in strategic collaborating and raising funds from both public and private sources. Mr. Shaw's direct international experience includes Canada, Europe, South East Asia, China, and Japan. Previously Mr. Shaw served as CEO of OpGen Inc., a nanotechnology genomics company based in Wisconsin. Prior to this, he was interim President of Bank on a Cure, a global study project of the International Myeloma Foundation, the first comprehensive myelomaspecific cancer patient DNA bank. During his tenure, Mr. Shaw worked to coordinate and develop a fully functioning enterprise, combining multiple institutions and patient support groups. Simultaneously, he served as President of AusAmerican Group, Inc.'s North America division, AusAmerican Group Inc. is a consulting firm that provides a full range of business services to Australian and American corporations, from medical group practices to start-up biotechnology companies seeking to introduce products or services into the Australian or U.S. marketplace. From 1999 to 2004, Mr. Shaw was Managing Director and CEO of Ambri Limited, Inc., the medical division of Pacific Dunlop Limited, an Australian conglomerate.

Ambri develops nanotechnology and biotechnology diagnostic devices. Under his leadership, Ambri listed on the Australian stock exchange, raising more than \$32 million. At the time, this was the largest biotechnology listing in Australia to date. He also negotiated strategic investments from Dow Corning and Genencor, Inc. Previously he served as CEO and Chairperson of the Board of Quantech Inc., a biosensor technology company, and CEO of Cathra International, a bacteriological testing company. He has held senior executive positions with KVet/KVL Limited, a human and veterinarian medical company, QuadraLogics, which specializes in cancer therapeutics and Johnson & Johnson. In 2002 and 2003, Mr. Shaw spoke at the Australian/American Leadership Conference conducted at the White House. He also participated as a speaker at the Commonwealth Government's Australian Development Congress in 1999, 2000, 2001 and was a member of the "Prime Minister's Science Council" of Australia. He has been a frequent guest speaker at both U.S. and international government and academic forums regarding the development and commercialization of biotechnology innovations.